Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLUTE benralizumab phase 3 trial in eosinophilic COPD
NL-OMON52490Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Benralizumab plus background triple therapy with Placebo plus background triple therapy (2 arms). Primary endpoint: Annualized rate of moderate or severe COPD exacerbations. Started Jan 2021; status: recruiting.
02
Drugs
benralizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON52490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52490.